pdl2 Search Results


anti pd l2 rabbit polyclonal antibody  (Bioss)
92
Bioss anti pd l2 rabbit polyclonal antibody
Anti Pd L2 Rabbit Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/10__31557_slash_apjcp__2025__26__10__3769-67-16-22?v=Bioss
Average 92 stars, based on 1 article reviews
anti pd l2 rabbit polyclonal antibody - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
pd l2 proteintech  (Proteintech)
94
Proteintech pd l2 proteintech
Overall survival rate of ALL patients with and without prognostic factors. Kaplan–Meier (KM)survival curves and prognostic factors were compared between groups using the log-rank test (red indicates immunostaining-positive groups, black indicates immunostaining-negative groups. 95% confidence intervals (CI) have been added to all KM graphs. ( A ) OS was significantly shortened in the AKR1B10-positive group ( p < 0.05). ( B ) OS was significantly shortened in the AKR1C3-positive group ( p < 0.05). ( C ) There was no significant difference in OS between the AKR1B1-positive and -negative groups (NS). ( D ) There was no significant difference in OS rate between the MRP1-positive and -negative groups. ( E ) There was no significant difference in OS between the <t>PD-L2-positive</t> and -negative groups. ( F ) There was no significant difference in OS between the CYP2B6-positive and -negative groups. It is known that the log-rank test, a common test for KM curves, does not allow for reliable statistical conclusions because the sample size is too small. Therefore, we retested and using the Pet-Pet-Wilcoxon method, which is often used for small samples. The results were generally the same, except for MRP1 in D, which changed from NS to p < 0.05. However, this change did not have much impact on the overall discussion.
Pd L2 Proteintech, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/pmc12842254-148-143-144?v=Proteintech
Average 94 stars, based on 1 article reviews
pd l2 proteintech - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
anti cd273 apc vio 770  (Miltenyi Biotec)
91
Miltenyi Biotec anti cd273 apc vio 770
Overall survival rate of ALL patients with and without prognostic factors. Kaplan–Meier (KM)survival curves and prognostic factors were compared between groups using the log-rank test (red indicates immunostaining-positive groups, black indicates immunostaining-negative groups. 95% confidence intervals (CI) have been added to all KM graphs. ( A ) OS was significantly shortened in the AKR1B10-positive group ( p < 0.05). ( B ) OS was significantly shortened in the AKR1C3-positive group ( p < 0.05). ( C ) There was no significant difference in OS between the AKR1B1-positive and -negative groups (NS). ( D ) There was no significant difference in OS rate between the MRP1-positive and -negative groups. ( E ) There was no significant difference in OS between the <t>PD-L2-positive</t> and -negative groups. ( F ) There was no significant difference in OS between the CYP2B6-positive and -negative groups. It is known that the log-rank test, a common test for KM curves, does not allow for reliable statistical conclusions because the sample size is too small. Therefore, we retested and using the Pet-Pet-Wilcoxon method, which is often used for small samples. The results were generally the same, except for MRP1 in D, which changed from NS to p < 0.05. However, this change did not have much impact on the overall discussion.
Anti Cd273 Apc Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/pmc08910063-190-18-25?v=Miltenyi+Biotec
Average 91 stars, based on 1 article reviews
anti cd273 apc vio 770 - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier
pd l2 expression plasmid  (OriGene)
91
OriGene pd l2 expression plasmid
Overall survival rate of ALL patients with and without prognostic factors. Kaplan–Meier (KM)survival curves and prognostic factors were compared between groups using the log-rank test (red indicates immunostaining-positive groups, black indicates immunostaining-negative groups. 95% confidence intervals (CI) have been added to all KM graphs. ( A ) OS was significantly shortened in the AKR1B10-positive group ( p < 0.05). ( B ) OS was significantly shortened in the AKR1C3-positive group ( p < 0.05). ( C ) There was no significant difference in OS between the AKR1B1-positive and -negative groups (NS). ( D ) There was no significant difference in OS rate between the MRP1-positive and -negative groups. ( E ) There was no significant difference in OS between the <t>PD-L2-positive</t> and -negative groups. ( F ) There was no significant difference in OS between the CYP2B6-positive and -negative groups. It is known that the log-rank test, a common test for KM curves, does not allow for reliable statistical conclusions because the sample size is too small. Therefore, we retested and using the Pet-Pet-Wilcoxon method, which is often used for small samples. The results were generally the same, except for MRP1 in D, which changed from NS to p < 0.05. However, this change did not have much impact on the overall discussion.
Pd L2 Expression Plasmid, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/us11673951-131-1-7?v=OriGene
Average 91 stars, based on 1 article reviews
pd l2 expression plasmid - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier
pd l2 rabbit monoclonal antibody  (Proteintech)
94
Proteintech pd l2 rabbit monoclonal antibody
Overall survival rate of ALL patients with and without prognostic factors. Kaplan–Meier (KM)survival curves and prognostic factors were compared between groups using the log-rank test (red indicates immunostaining-positive groups, black indicates immunostaining-negative groups. 95% confidence intervals (CI) have been added to all KM graphs. ( A ) OS was significantly shortened in the AKR1B10-positive group ( p < 0.05). ( B ) OS was significantly shortened in the AKR1C3-positive group ( p < 0.05). ( C ) There was no significant difference in OS between the AKR1B1-positive and -negative groups (NS). ( D ) There was no significant difference in OS rate between the MRP1-positive and -negative groups. ( E ) There was no significant difference in OS between the <t>PD-L2-positive</t> and -negative groups. ( F ) There was no significant difference in OS between the CYP2B6-positive and -negative groups. It is known that the log-rank test, a common test for KM curves, does not allow for reliable statistical conclusions because the sample size is too small. Therefore, we retested and using the Pet-Pet-Wilcoxon method, which is often used for small samples. The results were generally the same, except for MRP1 in D, which changed from NS to p < 0.05. However, this change did not have much impact on the overall discussion.
Pd L2 Rabbit Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/pmc11319731__41467_2024_51386_MOESM1_ESM-128-29-33?v=Proteintech
Average 94 stars, based on 1 article reviews
pd l2 rabbit monoclonal antibody - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
pd l2  (ProSci Incorporated)
90
ProSci Incorporated pd l2
Overall survival rate of ALL patients with and without prognostic factors. Kaplan–Meier (KM)survival curves and prognostic factors were compared between groups using the log-rank test (red indicates immunostaining-positive groups, black indicates immunostaining-negative groups. 95% confidence intervals (CI) have been added to all KM graphs. ( A ) OS was significantly shortened in the AKR1B10-positive group ( p < 0.05). ( B ) OS was significantly shortened in the AKR1C3-positive group ( p < 0.05). ( C ) There was no significant difference in OS between the AKR1B1-positive and -negative groups (NS). ( D ) There was no significant difference in OS rate between the MRP1-positive and -negative groups. ( E ) There was no significant difference in OS between the <t>PD-L2-positive</t> and -negative groups. ( F ) There was no significant difference in OS between the CYP2B6-positive and -negative groups. It is known that the log-rank test, a common test for KM curves, does not allow for reliable statistical conclusions because the sample size is too small. Therefore, we retested and using the Pet-Pet-Wilcoxon method, which is often used for small samples. The results were generally the same, except for MRP1 in D, which changed from NS to p < 0.05. However, this change did not have much impact on the overall discussion.
Pd L2, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/pm37547182-130-84-87?v=ProSci+Incorporated
Average 90 stars, based on 1 article reviews
pd l2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
pd l2  (Biorbyt)
90
Biorbyt pd l2
Less PD-L1+ monocytes in patients with AAV. (A) Percentages of PD-L1+ monocytes in HC (n=20) and AAV patients (n=26). (B) Surface expression of PD-L1 (MFI) on classical (CD14+CD16-), intermediate (CD14+CD16+), and non-classical monocytes (CD14dim CD16++) in healthy control donors (n=20) and AAV patients (n=26). (C–E) Percentages of <t>PD-L2+,</t> CD80+, and CD86+ monocytes in HC and AAV patients (n=9-10 each cohort). Mann-Whitney (A, B, D) test or unpaired t-test (C, E) were applied. **P<0.01; ***P<0.001. Bar graph shows mean ± SEM. AAV, ANCA-associated vasculitis; HC, healthy control donors; MFI, mean fluorescence intensity; PD-L1, Programmed death-ligand 1; ns, statistically not significant.
Pd L2, supplied by Biorbyt, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/pmc08183471-100-10-8?v=Biorbyt
Average 90 stars, based on 1 article reviews
pd l2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cd273 pd l2  (fluidigm)
91
fluidigm cd273 pd l2
Less PD-L1+ monocytes in patients with AAV. (A) Percentages of PD-L1+ monocytes in HC (n=20) and AAV patients (n=26). (B) Surface expression of PD-L1 (MFI) on classical (CD14+CD16-), intermediate (CD14+CD16+), and non-classical monocytes (CD14dim CD16++) in healthy control donors (n=20) and AAV patients (n=26). (C–E) Percentages of <t>PD-L2+,</t> CD80+, and CD86+ monocytes in HC and AAV patients (n=9-10 each cohort). Mann-Whitney (A, B, D) test or unpaired t-test (C, E) were applied. **P<0.01; ***P<0.001. Bar graph shows mean ± SEM. AAV, ANCA-associated vasculitis; HC, healthy control donors; MFI, mean fluorescence intensity; PD-L1, Programmed death-ligand 1; ns, statistically not significant.
Cd273 Pd L2, supplied by fluidigm, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/pmc07729358-17-0-6?v=fluidigm
Average 91 stars, based on 1 article reviews
cd273 pd l2 - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier
carbon-based nanocarriers pdl 2  (NanoCarrier Co)
90
NanoCarrier Co carbon-based nanocarriers pdl 2
Less PD-L1+ monocytes in patients with AAV. (A) Percentages of PD-L1+ monocytes in HC (n=20) and AAV patients (n=26). (B) Surface expression of PD-L1 (MFI) on classical (CD14+CD16-), intermediate (CD14+CD16+), and non-classical monocytes (CD14dim CD16++) in healthy control donors (n=20) and AAV patients (n=26). (C–E) Percentages of <t>PD-L2+,</t> CD80+, and CD86+ monocytes in HC and AAV patients (n=9-10 each cohort). Mann-Whitney (A, B, D) test or unpaired t-test (C, E) were applied. **P<0.01; ***P<0.001. Bar graph shows mean ± SEM. AAV, ANCA-associated vasculitis; HC, healthy control donors; MFI, mean fluorescence intensity; PD-L1, Programmed death-ligand 1; ns, statistically not significant.
Carbon Based Nanocarriers Pdl 2, supplied by NanoCarrier Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/pmc10785617-183-10-34?v=NanoCarrier+Co
Average 90 stars, based on 1 article reviews
carbon-based nanocarriers pdl 2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
heteroleptic d-shaped binuclear complex [(pdl’)2(l1)1(l2)1](x)4  (Verlag GmbH)
90
Verlag GmbH heteroleptic d-shaped binuclear complex [(pdl’)2(l1)1(l2)1](x)4
Less PD-L1+ monocytes in patients with AAV. (A) Percentages of PD-L1+ monocytes in HC (n=20) and AAV patients (n=26). (B) Surface expression of PD-L1 (MFI) on classical (CD14+CD16-), intermediate (CD14+CD16+), and non-classical monocytes (CD14dim CD16++) in healthy control donors (n=20) and AAV patients (n=26). (C–E) Percentages of <t>PD-L2+,</t> CD80+, and CD86+ monocytes in HC and AAV patients (n=9-10 each cohort). Mann-Whitney (A, B, D) test or unpaired t-test (C, E) were applied. **P<0.01; ***P<0.001. Bar graph shows mean ± SEM. AAV, ANCA-associated vasculitis; HC, healthy control donors; MFI, mean fluorescence intensity; PD-L1, Programmed death-ligand 1; ns, statistically not significant.
Heteroleptic D Shaped Binuclear Complex [(Pdl’)2(l1)1(l2)1](X)4, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/pm28640963-59-17-8?v=Verlag+GmbH
Average 90 stars, based on 1 article reviews
heteroleptic d-shaped binuclear complex [(pdl’)2(l1)1(l2)1](x)4 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
logic 2 system  (PRODESIGN GmbH)
90
PRODESIGN GmbH logic 2 system
Less PD-L1+ monocytes in patients with AAV. (A) Percentages of PD-L1+ monocytes in HC (n=20) and AAV patients (n=26). (B) Surface expression of PD-L1 (MFI) on classical (CD14+CD16-), intermediate (CD14+CD16+), and non-classical monocytes (CD14dim CD16++) in healthy control donors (n=20) and AAV patients (n=26). (C–E) Percentages of <t>PD-L2+,</t> CD80+, and CD86+ monocytes in HC and AAV patients (n=9-10 each cohort). Mann-Whitney (A, B, D) test or unpaired t-test (C, E) were applied. **P<0.01; ***P<0.001. Bar graph shows mean ± SEM. AAV, ANCA-associated vasculitis; HC, healthy control donors; MFI, mean fluorescence intensity; PD-L1, Programmed death-ligand 1; ns, statistically not significant.
Logic 2 System, supplied by PRODESIGN GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdl2/pm38901644-52-2-1?v=PRODESIGN+GmbH
Average 90 stars, based on 1 article reviews
logic 2 system - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Overall survival rate of ALL patients with and without prognostic factors. Kaplan–Meier (KM)survival curves and prognostic factors were compared between groups using the log-rank test (red indicates immunostaining-positive groups, black indicates immunostaining-negative groups. 95% confidence intervals (CI) have been added to all KM graphs. ( A ) OS was significantly shortened in the AKR1B10-positive group ( p < 0.05). ( B ) OS was significantly shortened in the AKR1C3-positive group ( p < 0.05). ( C ) There was no significant difference in OS between the AKR1B1-positive and -negative groups (NS). ( D ) There was no significant difference in OS rate between the MRP1-positive and -negative groups. ( E ) There was no significant difference in OS between the PD-L2-positive and -negative groups. ( F ) There was no significant difference in OS between the CYP2B6-positive and -negative groups. It is known that the log-rank test, a common test for KM curves, does not allow for reliable statistical conclusions because the sample size is too small. Therefore, we retested and using the Pet-Pet-Wilcoxon method, which is often used for small samples. The results were generally the same, except for MRP1 in D, which changed from NS to p < 0.05. However, this change did not have much impact on the overall discussion.

Journal: Journal of Clinical Medicine

Article Title: A New Histology-Based Prognostic Index for Acute Lymphoblastic Leukemia: Preliminary Results of the “ALL Urayasu Classification”

doi: 10.3390/jcm15020768

Figure Lengend Snippet: Overall survival rate of ALL patients with and without prognostic factors. Kaplan–Meier (KM)survival curves and prognostic factors were compared between groups using the log-rank test (red indicates immunostaining-positive groups, black indicates immunostaining-negative groups. 95% confidence intervals (CI) have been added to all KM graphs. ( A ) OS was significantly shortened in the AKR1B10-positive group ( p < 0.05). ( B ) OS was significantly shortened in the AKR1C3-positive group ( p < 0.05). ( C ) There was no significant difference in OS between the AKR1B1-positive and -negative groups (NS). ( D ) There was no significant difference in OS rate between the MRP1-positive and -negative groups. ( E ) There was no significant difference in OS between the PD-L2-positive and -negative groups. ( F ) There was no significant difference in OS between the CYP2B6-positive and -negative groups. It is known that the log-rank test, a common test for KM curves, does not allow for reliable statistical conclusions because the sample size is too small. Therefore, we retested and using the Pet-Pet-Wilcoxon method, which is often used for small samples. The results were generally the same, except for MRP1 in D, which changed from NS to p < 0.05. However, this change did not have much impact on the overall discussion.

Article Snippet: Primary antibodies against key proteins involved in anticancer drug metabolism were used: (1) GRP94: Proteintech (Rosemont, IL, USA), clone 1H10B7 (monoclonal antibody); (2) CYP3A4: Sigma-Aldrich (St. Louis, MO, USA), SAB1400064 (polyclonal antibody against CYP3A4); (3) AKR1C3: Proteintech 11194-1-AP (polyclonal antibody against AKR1C3); (4) MDR1 (P-glycoprotein): Proteintech, 22336-1-AP (polyclonal antibody against MDR1); (5) MRP1 (CD9): Proteintech, 60232-1-IG (monoclonal antibody against full-length MRP1); (6) TGF-beta1: Proteintech, 21898-1-AP (polyclonal antibody against TGF-beta); (7) GRP78: Proteintech, 66574-1-IG (monoclonal antibody against full-length GRP78); (8) Glutathione S-transferase-κ1 (GST): Proteintech, 14535-1-AP (polyclonal antibody against GST1); (9) Thymidine phosphorylase: Abcam (Cambridge, UK), ab226917 (polyclonal antibody); (10) MRP4 (ABCC4): SANTA CRUZ BIOTECHNOLOGY (Dallas, TX, USA), SC-376262 (monoclonal antibody against MRP4); (11) CYP2B6: LifeSpan BioSciences, Inc. (Seattle, WA, USA), LS-C352084 (polyclonal antibody against CYP2B6); (12) TNF1-alpha: Sigma-Aldrich, SAB4502982 (polyclonal antibody against TNF1-alpha) (13) PD-1; (14) PD-L1: Proteintech, 66248-1-IG, monoclonal antibody, clone 2B11D11; (15) PD-L2: Proteintech, 18251-1-AP16, rabbit IgG polyclonal antibody; (16) P53: Cell Signaling Technology, Inc. (3 Trask Lane, Danvers, MA, USA), DO-7 mouse monoclonal antibody #48818; (17) c-MYC: Abcam (Kendall Square, Cambridge, MA, USA), Y69 clone ab32072; (18) ENT-1: Proteintech, 1337-1-AP, IgG polyclonal antibody; (19) AKR1B1: Sigma-Aldrich (3050 Spruce Street, Saint Louis, MO, USA), polyclonal antibody HPA052751; and (20) AKR1B10: Sigma-Aldrich (3050 Spruce Street, Saint Louis, MO, USA), monoclonal antibody HPA020280.

Techniques: Immunostaining

Less PD-L1+ monocytes in patients with AAV. (A) Percentages of PD-L1+ monocytes in HC (n=20) and AAV patients (n=26). (B) Surface expression of PD-L1 (MFI) on classical (CD14+CD16-), intermediate (CD14+CD16+), and non-classical monocytes (CD14dim CD16++) in healthy control donors (n=20) and AAV patients (n=26). (C–E) Percentages of PD-L2+, CD80+, and CD86+ monocytes in HC and AAV patients (n=9-10 each cohort). Mann-Whitney (A, B, D) test or unpaired t-test (C, E) were applied. **P<0.01; ***P<0.001. Bar graph shows mean ± SEM. AAV, ANCA-associated vasculitis; HC, healthy control donors; MFI, mean fluorescence intensity; PD-L1, Programmed death-ligand 1; ns, statistically not significant.

Journal: Frontiers in Immunology

Article Title: CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1

doi: 10.3389/fimmu.2021.673912

Figure Lengend Snippet: Less PD-L1+ monocytes in patients with AAV. (A) Percentages of PD-L1+ monocytes in HC (n=20) and AAV patients (n=26). (B) Surface expression of PD-L1 (MFI) on classical (CD14+CD16-), intermediate (CD14+CD16+), and non-classical monocytes (CD14dim CD16++) in healthy control donors (n=20) and AAV patients (n=26). (C–E) Percentages of PD-L2+, CD80+, and CD86+ monocytes in HC and AAV patients (n=9-10 each cohort). Mann-Whitney (A, B, D) test or unpaired t-test (C, E) were applied. **P<0.01; ***P<0.001. Bar graph shows mean ± SEM. AAV, ANCA-associated vasculitis; HC, healthy control donors; MFI, mean fluorescence intensity; PD-L1, Programmed death-ligand 1; ns, statistically not significant.

Article Snippet: The following antibodies or stainings were used: CMTM6 (biorbyt), PD-L1, PD-L2, CD80, CD86, CD4, CD25 (all BioLegend), and CFSE (Molecular Probes).

Techniques: Expressing, Control, MANN-WHITNEY, Fluorescence